Declining NAD induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging
Gomes AP, Price NL, Ling AJY, et al.
Key finding
Short-term NMN restores aged-mouse muscle NAD+ and reverses pseudohypoxic mitochondrial dysfunction, implicating NAD+ decline as a causal aging driver.
Summary
Mechanistic mouse study from the Sinclair lab showing that age-related NAD+ decline induces a pseudohypoxic state in which HIF-1α stabilizes under normoxia, disrupting SIRT1-mediated signaling from nucleus to mitochondria and causing mitochondrial-encoded OXPHOS gene expression to fall. Aged (22-month) C57BL/6 mice had ~50% lower muscle NAD+ than young (6-month) controls, paired with reduced mitochondrial respiratory capacity and impaired PGC-1α/β signaling. Critically, one week of intraperitoneal NMN at 500 mg/kg/day restored muscle NAD+ to youthful levels, normalized the nuclear-mitochondrial communication axis, and reversed key features of mitochondrial dysfunction — effectively making 22-month-old muscle resemble that of 6-month-old animals at the transcriptomic and respirometric level. The work cemented NAD+ as a causal, reversible mediator of mitochondrial aging and served as the experimental foundation for subsequent NMN trials in humans. The rapid rescue also demonstrated that NAD+ deficit, not accumulated damage, drives a meaningful portion of the aged phenotype.
Access the full paper
Related research
Nature Metabolism · 2019
Slc12a8 is a nicotinamide mononucleotide transporter
Oral NMN reaches tissues intact via a dedicated intestinal transporter.
Science · 2021
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
NMN improved skeletal muscle insulin sensitivity and gene expression in postmenopausal women.
Scientific Reports · 2023
Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation
12 weeks of 250 mg/day NMN in middle-aged adults raised blood NAD+ and was associated with reduced arterial stiffness (CAVI) vs. placebo.